Plain-English translation of NCT04955899 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is an early-stage study testing the Galvani neuromodulation system—a surgically implanted device that sends gentle electrical signals to a nerve connected to your spleen—in people with rheumatoid arthritis (RA) who have not responded well to at least two other biologic treatments. Over 5 months, you would have surgery to place the device, recover for 4 weeks, then receive active stimulation for 12 weeks while researchers carefully watch for safety and how well the treatment works. After the study ends, you would have the option to join a longer follow-up program lasting up to 5 years.
Many people with rheumatoid arthritis don't respond well enough to current biologic medications, leaving them with ongoing pain and inflammation. This trial is exploring whether stimulating a specific nerve can help calm the immune system and reduce RA symptoms in people who haven't had success with other treatments.
You likely qualify if…
You likely don't qualify if…
You would spend about 4 weeks in a screening phase, then have surgery to implant the small device under your skin. After 4 weeks of recovery, the device would be turned on for 12 weeks of active stimulation, and you would visit the clinic on scheduled days for check-ups and to make sure everything is working safely. The entire study takes about 5 months, and researchers may adjust how the device works at specific checkpoints if needed.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
Netherlands
United Kingdom